Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J analgesic

This article was originally published in The Tan Sheet

Executive Summary

McNeil is reportedly preparing for the market launch of a new OTC ibuprofen product to be called Zymaxin. McNeil Consumer received FDA approval for an ANDA covering a 200 mg ibuprofen tablet in March and filed for the Zymaxin trademark in March 1993. J&J announced its re-entry into the ibuprofen pain-reliever market in July with the launch of its Arthritis Foundation line, which includes an ibuprofen-based product ("The Tan Sheet" July 11, p. 8). J&J got out of ibuprofen products in 1992 when it discontinued marketing Medipren
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083228

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel